Chemosensitivity testing for gastrointestinal cancer: Survival benefit potential and limitations

Anti-Cancer Drugs

Volumn 14, Issue 9, 2003, Pages 715-723

  Kim, Ryungsa ^a   Emi, Manabu ^a   Tanabe, Kazuaki ^a   Uchida, Yoko ^a   Toge, Tetsuya ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Adjuvant chemotherapy; Chemosensitivity testing; Gastrointestinal cancer; Survival benefit

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; IRINOTECAN; MITOMYCIN C; UFT;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOSENSITIVITY; DIGESTIVE SYSTEM CANCER; DRUG SENSITIVITY; HUMAN; METASTASIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW;

EID: 0242319841     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200310000-00005     Document Type: Review

References (77)

1. Salmon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS, Moon TE. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 1978; 298:1321-1327.
2. Cole SP. Rapid chemosensitivity testing of human lung tumor cells using the MTT assay. Cancer Chemother Pharmacol 1986; 17:259-263.
3. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47:936-942.
4. Hoffman RM. Three-dimensional histoculture: origins and applications in cancer research. Cancer Cells 1991; 3:86-92.
5. Hoffman RM. In vitro sensitivity assays in cancer: a review, analysis, and prognosis. J Clin Lab Anal 1991; 5:133-143.
6. Furukawa T, Kubota T, Hoffman RM. Clinical applications of the histoculture drug response assay. Clin Cancer Res 1995; 1:305-311.
7. Inaba M, Tashiro T, Sato S, Ohnishi Y, Tanisaka K, Kobayashi H, et al. In vitro-in vivo correlation in anticancer drug sensitivity test using AUC-based concentrations and collagen gel droplet-embedded culture. Oncology 1996; 53:250-257.
8. Takamura Y, Kobayashi H, Taguchi T, Motomura K, Inaji H, Noguchi S. Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers. Int J Cancer 2002; 98:450-455.
9. Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, et al. Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res 1995; 1:1537-1543.
10. Yamaue H, Tanimura H, Nakamori M, Noguchi K, Iwahashi M, Tani M, et al. Clinical evaluation of chemosensitivity testing for patients with colorectal cancer using MTT assay. Dis Colon Rectum 1996; 39:416-422.
11. Janunger KG, Hafstrom L, Nygren P, Glimelius B. SBU-group: Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 2001 ; 40:309-326.
12. Kim R, Yoshida K, Toge T. Current status and future perspectives of post-operative adjuvant therapy for gastric carcinoma. Anticancer Res 2002; 22:283-289.
13. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17:319-323.
14. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998; 34:1715-1720.
15. Kruijtzer CM, Boot H, Beijnen JH, Lochs HL, Parnis FX, Planting AS, et al. Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. Ann Oncol 2003; 14:197-204.
16. Haller DG, Misset JL. Docetaxel in advanced gastric cancer. Anticancer Drugs 2002; 13:451-460.
17. Von Hoff DD. Human tumor cloning assays: applications in clinical oncology and new antineoplastic agent development. Cancer Metastasis Rev 1988; 7:357-371.
18. Weisenthal LM, Lippman ME. Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat Rep 1985; 69:615-632.
19. Kondo T, Imamura T, Ichihashi H. In vitro test for sensitivity of tumor to carcinostatic agents. Gann 1966; 57:113-121.
20. Yamauchi M, Satta T, Ito A, Kondo T, Takagi H. A feasibility study of the SDI test for the evaluation of gastrointestinal cancer sensitivity to anticancer drugs. J Surg Oncol 1991; 47:253-260.
21. Sevin BU, Peng ZL, Perras JP, Ganjei P, Penalver M, Averette HE. Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. Gynecol Oncol 1988; 31:191-204.
22. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55:5276-5282.
23. Noso Y, Niimi K, Nishiyama M, Hirabayashi N, Toge T, Niimoto M, et al. Clinical studies on a new screening assay for anticancer agents using nude mice and isotopic evaluation. Cancer Res 1987; 47:6418-6422.
24. Favre R, Marotia L, Drancourt M, Jaquemier J, Delpero JR, Guerinel G, et al. 6-day subrenal capsule assay (SRCA) as a predictor of the response of advanced cancers to chemotherapy. Eur J Cancer Clin Oncol 1986; 22:1171-1178.
25. Nishiyama M, Hirono M, Takagami S, Kim R, Saeki T, Kirihara Y, et al. The histological assessment and evaluation of a 4 day subrenal capsule assay by the percentage inhibition of DNA/protein. Jpn J Surg 1989; 19:403-409.
26. Yamauchi M, Satta T, Ito A, Kondo K, Akiyama S, Ito K, et al. Subrenal capsule assay using nude mice as a predictor of the response of the gastric cancer to chemotherapy. J Surg Oncol 1991; 47:98-101.
27. Yanagawa E, Nishiyama M, Saeki T, Kim R, Jinushi K, Kirihara Y, et al. Chemosensitivity tests in colorectal cancer patients. Jpn J Surg 1989; 19:432-438.
28. Bellamy WT. Prediction of response to drug therapy of cancer. A review of in vitro assays. Drugs 1992; 44:690-708.
29. Letwin R. Chemosensitivity testing. Clin J Oncol Nurs 2001; 5:195-200.
30. Yamaue H, Tanimura H, Tsunoda T, Tani M, Iwahashi M, Noguchi K, et al. Chemosensitivity testing with highly purified fresh human tumor cells with the MTT colorimetric assay. Eur J Cancer 1991; 27:1258-1263.
31. Kawamura H, Ikeda K, Takiyama I, Terashima M. The usefulness of the ATP assay with serum-free culture for chemosensitivity testing of gastrointestinal cancer. Eur J Cancer 1997; 33:960-966.
32. Esumi H, Izuishi K, Kato K, Hashimoto K, Kurashima Y, Kishimoto A, et al. Hypoxia and nitric oxide treatment confer tolerance to glucose starvation in a 5′-AMP-activated protein kinase-dependent manner. J Biol Chem 2002; 277:32791-32798.
33. Chen EY, Mazure NM, Cooper JA, Giaccia AJ. Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res 2001; 61:2429-2433.
34. Brandes LM, Lin ZP, Patierno SR, Kennedy KA. Reversal of physiological stress-induced resistance to topoisomerase II inhibitors using an inducible phosphorylation site-deficient mutant of I kappa B alpha. Mol Pharmacol 2001;60:559-567.
35. Mellick AS, Day CJ, Weinstein SR, Griffiths LR, Morrison NA. Differential gene expression in breast cancer cell lines and stroma-tumor differences in microdissected breast cancer biopsies revealed by display array analysis. Int J Cancer 2002; 100:172-180.
36. Bosanquet AG, Burlton AR, Bell PB. Parameters affecting the ex vivo cytotoxic drug sensitivity of human hematopoietic cells. J Exp Ther Oncol 2002; 2:53-63.
37. Metzger R, Deglmann CJ, Hoerrlein S, Zapf S, Hilfrich J. Towards in vitro prediction of an in-vivo cytostatic response of human tumor cells with a fast chemosensitivity assay. Toxicology 2001; 166:97-108.
38. Yasuda H, Takada T, Wada K, Amano H, Isaka T, Yoshida M, et al. A new in-vitro drug sensitivity test (collagen-gel droplet embedded-culture drug sensitivity test) in carcinomas of pancreas and biliary tract: possible clinical utility. J Hepatobiliary Pancreat Surg 1998; 5:261-268.
39. Von Hoff DD, Clark GM, Stogdill BJ, Sarosdy MF, O'Brien MT, Casper JT, et al. Prospective clinical trial of a human tumor cloning system. Cancer Res 1983; 43:1926-1931.
40. Weiss G, Von Hoff DD. Human tumor cloning assay: Clinical applications for ovarian, gastric, pancreatic, and colorectal cancers. Semin Oncol 1985; 12:69-74.
41. Kobayashi H. Development of a new in vitro chemosensitivity test using collagen gel droplet embedded culture and image analysis for clinical usefulness. Rec Results Cancer Res 2003; 161:48-61.
42. Yamaue H, Tanimura H, Noguchi K, Hotta T, Tani M, Tsunoda T, et al. Chemosensitivity testing of fresh human gastric cancer with highly purified tumour cells using the MTT assay. Br J Cancer 1992; 66:794-799.
43. 3H] incorporation with the response in case of human tumor chemotherapy. Jpn J Surg 1986; 16:195-201.
44. Higashiyama M, Kodama K, Yokouchi H, Takami K, Nakagawa H, Imamura F, et al. Cisplatin-based chemotherapy for postoperative recurrence in non-small cell lung cancer patients: relation of the in vitro chemosensitive test to clinical response. Oncol Rep 2001; 8:279-283.
45. Konecny G, Crohns C, Pegram M, Felber M, Lude S, Kurbacher C, et al. Correlation of drug response with the ATP tumor chemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol 2000; 77:258-263.
46. Baba H, Takeuchi H, Inutsuka S, Yamamoto M, Endo K, Ohno S, et al. Clinical value of SDI test for predicting effect of postoperative chemotherapy for patients with gastric cancer. Semin Surg Oncol 1994; 10:140-144.
47. Abe S, Kubota T, Matsuzaki SW, Otani Y, Watanabe M, Teramoto T, et al. Chemosensitivity test is useful in evaluating the appropriate adjuvant cancer chemotherapy for stage III non-scirrhous and scirrhous gastric cancers. Anticancer Res 1999; 19:4581-4586.
48. Kabeshima Y, Kubota T, Watanabe M, Hasegawa H, Furukawa T, Kitajima M. Clinical usefulness of chemosensitivity test for advanced colorectal cancer. Anticancer Res 2002; 22:3033-3037.
49. Kubota T, Otani Y, Furukawa T, Hasegawa H, Watanabe M, Kitajima M. Chemosensitivity testing-present and future in Japan. Rec Results Cancer Res 2003; 161:231-241.
50. Denda T, Saisho H, Yoshikawa M, Ebara M, Ohto M, Fujimoto S, et al. Chemosensitivity test for repeated arterial infusion chemotherapy by reservoir for unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 1995; 10:446-453.
51. Yamaue H, Tani M, Onishi H, Kinoshita H, Nakamori M, Yokoyama S, et al. Locoregional chemotherapy for patients with pancreatic cancer intra-arterial adjuvant chemotherapy after pancreatectomy with portal vein resection. Pancreas 2002; 25:366-372.
52. Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, et al. Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 2002; 24:437-442.
53. Neuber K. Treosulfan in the treatment of metastatic melanoma: from chemosensitivity testing to clinical trials. Rec Results Cancer Res 2003; 161:159-179.
54. Cree IA, Kurbacher CM. Individualizing chemotherapy for solid tumors - is there any alternative? Anticancer Drugs 1997; 8:541-548.
55. Von Hoff DD, Clark GM, Forseth BJ, Cowan JD. Simultaneous in vitro drug sensitivity testing on tumors from different sites in the same patient. Cancer 1986; 58:1007-1013.
56. Hunter EM, Sutherland LA, Cree IA, Dewar JA, Preece PE, Wood RA, et al. Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay. Eur J Surg Oncol 1993; 19:242-429.
57. Mercer SJ, Somers SS, Knight LA, Whitehouse PA, Sharma S, Di Nicolantonio F, et al. Heterogeneity of chemosensitivity of esophageal and gastric carcinoma. Anticancer Drugs 2003; 14:397-403.
58. Adlard JW, Richman SD, Seymour MT, Quirke P. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 2002; 3:75-82.
59. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
60. Paik S, Bryant J, Tan-Chiu E, Yothers G, Park C, Wickerham DL, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000; 92:1991-1998.
61. Kim R, Tanabe K, Uchida Y, Osaki A, Toge T. The role of HER-2 oncoprotein in drug-sensitivity in breast cancer. Oncol Rep 2002; 9:3-9.
62. van Triest B, Pinedo HM, Blaauwgeers JL, van Diest PJ, Schoenmakers PS, Voorn DA, et al. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 2000; 6:1063-1072.
63. Terashima M, Fujiwara H, Takagane A, Abe K, Araya M, Irinoda T, et al. Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients. Eur J Cancer 2002; 38:2375-2381.
64. Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 2001; 61:8452-8458.
65. Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, Park J, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 2001; 98:10787-10789.
66. Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, et al. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 2002; 62:1139-1147.
67. Okutsu J, Tsunoda T, Kaneta Y, Katagiri T, Kitahara O, Zembutsu H, et al. Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis. Mol Cancer Ther 2002; 1:1035-1042.
68. Bertucci F, Houlgatte R, Benziane A, Granjeaud S, Adelaide J, Tagett R, et al. Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum Mol Genet 2000; 9:2981-2991.
69. Sotiriou C, Powles TJ, Dowsett M, Jazaeri AA, Feldman AL, Assersohn L, et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res Treat 2002; 4:R3.
70. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6:1322-1327.
71. Takabayashi A, Iwata S, Kawai Y, Kanai M, Taki Y, Takechi T, et al. Dihydropyrimidine dehydrogenase activity and mRNA expression in advanced gastric cancer analyzed in relation to effectiveness of preoperative 5-fluorouracil-based chemotherapy. lnt J Oncol 2000; 17:889-895.
72. Aschele C, Lonardi S, Monfardini S. Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev 2002; 28:27-47.
73. Ichikawa W, Uetake H, Shirota Y, Yamada H, Nishi N, Nihei Z, et al. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 2003; 9:786-791.
74. Kihara C, Tsunoda T, Tanaka T, Yamana H, Furukawa Y, Ono K, et al. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res 2001; 61:6474-6479.
75. Hofmann WK, de Vos S, Elashoff D, Gschaidmeier H, Hoelzer D, Koeffler HP, et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 2002; 359:481-486.
76. Chang JC, Wooten E, Elledge RM, Hilsenbeck S, Tsimelzon A, Mohsin S, et al. Gene expression profiles for docetaxel chemosensitivity. Proc Am Soc Clin Oncol 2002; 21:1700a.
77. Pusztai L, Ayers M, Stec J, Hortobagyi GN. Clinical application of cDNA microarrays in oncology. Oncologist 2003; 8:252-258.